SCHEMBL6795010

SCHEMBL6795010

CCOc1ccc(-c2ccccc2C(=O)Nc2ccc(NCCc3ccccn3)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.55
NPC1 O15118 8/20 0.55
KDM4E B2RXH2 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
MITF O75030 1/20 0.55
PKM P14618 1/20 0.55
TP53 P04637 3/20 0.53
GAA P10253 2/20 0.53
ALDH1A1 P00352 1/20 0.53
ALOX15 P16050 1/20 0.53
KMT2A Q03164 7/20 0.52
MEN1 O00255 6/20 0.52
HTT P42858 3/20 0.52
LMNA P02545 2/20 0.52
MAPT P10636 4/20 0.50
MAPK1 P28482 2/20 0.50
POLB P06746 2/20 0.49
APOBEC3A P31941 1/20 0.47
APOBEC3G Q9HC16 1/20 0.47
PPARG P37231 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6796259 0.91 NPC1 (0.50) RAB9ANPC1KDM4ESMN1; SMN2MITF
SCHEMBL6793336 0.91 RAB9A (0.65) RAB9ANPC1KDM4ESMN1; SMN2PKM
SCHEMBL6793936 0.90 NPC1 (0.53) RAB9ANPC1KDM4ESMN1; SMN2MITF
SCHEMBL6792042 0.90 NPC1 (0.52) RAB9ANPC1SMN1; SMN2TP53GAA
SCHEMBL6792821 0.89 GAA (0.48) RAB9ANPC1KDM4ESMN1; SMN2GAA
SCHEMBL6794937 0.89 NPC1 (0.48) RAB9ANPC1KDM4ESMN1; SMN2MITF
SCHEMBL6793719 0.89 SMO (0.49) RAB9ANPC1GAAALDH1A1KMT2A
SCHEMBL6792178 0.89 MAPT (0.50) RAB9ANPC1KDM4ESMN1; SMN2PKM
SCHEMBL6792973 0.89 NPC1 (0.47) RAB9ANPC1KDM4ESMN1; SMN2MITF
SCHEMBL6788552 0.88 RAB9A (0.51) RAB9ANPC1KDM4ESMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 RAB9A 3707/4885NPC1 64/4885KDM4E 3114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.